Literature DB >> 12525729

Mirtazapine induces REM sleep behavior disorder (RBD) in parkinsonism.

M Onofrj1, A L Luciano, A Thomas, D Iacono, G D'Andreamatteo.   

Abstract

Shortly after initiation of mirtazapine (a noradrenergic and serotonergic antidepressant) treatment in four patients with parkinsonism, the authors observed the appearance of REM sleep behavior disorder (RBD). In the two patients with severe motor symptoms, RBD was accompanied by hallucinations and confusion. These disturbances resolved with drug discontinuation, and remained resolved by 12- to 24-month follow-up, suggesting that RBD can be triggered by a drug lacking anticholinergic activity.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12525729     DOI： 10.1212/01.wnl.0000042084.03066.c0

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  22 in total

Review 1.  REM sleep behaviour disorder in older individuals: epidemiology, pathophysiology and management.

Authors:  Lynn Marie Trotti
Journal:  Drugs Aging       Date:  2010-06-01       Impact factor: 3.923

2.  Probable rapid eye movement sleep behavior disorder increases risk for mild cognitive impairment and Parkinson disease: a population-based study.

Authors:  Brendon P Boot; Bradley F Boeve; Rosebud O Roberts; Tanis J Ferman; Yonas E Geda; V Shane Pankratz; Robert J Ivnik; Glenn E Smith; Eric McDade; Teresa J H Christianson; David S Knopman; Eric G Tangalos; Michael H Silber; Ronald C Petersen
Journal:  Ann Neurol       Date:  2012-01       Impact factor: 10.422

3.  Violent dreaming and antidepressant drugs: or how paroxetine made me dream that I was fighting Saddam Hussein.

Authors:  James M Parish
Journal:  J Clin Sleep Med       Date:  2007-08-15       Impact factor: 4.062

4.  Update on the Diagnosis and Management of Sleep Disturbances in Dementia.

Authors:  Bradley F Boeve
Journal:  Sleep Med Clin       Date:  2008-09

5.  The Role of the Serotonergic System in REM Sleep Behavior Disorder.

Authors:  Dario Arnaldi; Francesco Famà; Fabrizio De Carli; Silvia Morbelli; Michela Ferrara; Agnese Picco; Jennifer Accardo; Alberto Primavera; Gianmario Sambuceti; Flavio Nobili
Journal:  Sleep       Date:  2015-09-01       Impact factor: 5.849

Review 6.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

7.  Noradrenergic modulation of masseter muscle activity during natural rapid eye movement sleep requires glutamatergic signalling at the trigeminal motor nucleus.

Authors:  Peter B Schwarz; Saba Mir; John H Peever
Journal:  J Physiol       Date:  2014-05-23       Impact factor: 5.182

Review 8.  Sleep Disturbance, Cognitive Decline, and Dementia: A Review.

Authors:  Alexandra M V Wennberg; Mark N Wu; Paul B Rosenberg; Adam P Spira
Journal:  Semin Neurol       Date:  2017-08-24       Impact factor: 3.420

9.  Dream enactment behavior: review for the clinician.

Authors:  Marc Baltzan; Chun Yao; Dorrie Rizzo; Ron Postuma
Journal:  J Clin Sleep Med       Date:  2020-11-15       Impact factor: 4.062

10.  Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder.

Authors:  B F Boeve; M H Silber; T J Ferman; S C Lin; E E Benarroch; A M Schmeichel; J E Ahlskog; R J Caselli; S Jacobson; M Sabbagh; C Adler; B Woodruff; T G Beach; A Iranzo; E Gelpi; J Santamaria; E Tolosa; C Singer; D C Mash; C Luca; I Arnulf; C Duyckaerts; C H Schenck; M W Mahowald; Y Dauvilliers; N R Graff-Radford; Z K Wszolek; J E Parisi; B Dugger; M E Murray; D W Dickson
Journal:  Sleep Med       Date:  2013-03-07       Impact factor: 3.492
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.